Cargando...
Guillain-Barre syndrome induced by pembrolizumab and sunitinib: A case report
Pembrolizumab, an immune checkpoint inhibitor against the programmed death-1 pathway, has been used in combination with acitinib for the first-line treatment of advanced renal cell carcinoma. Neurotoxicity is a rare immune-related adverse event (irAE). The present study reports a case of Guillain-Ba...
Gardado en:
| Publicado en: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
D.A. Spandidos
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7265222/ https://ncbi.nlm.nih.gov/pubmed/32499912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2042 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|